Company profile
ACURX PHARMACEUTICALS, INC.
NASDAQ:ACXPBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| IBEZAPOLSTAT | phase2 | — | 2 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04247542 | phase2 | completed | 2020-03-06 | 2023-10-03 | Acurx Pharmaceuticals Inc. | ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection |
| NCT07513285 | phase2 | recruiting | 2026-08-06 | 2027-09-29 | Acurx Pharmaceuticals Inc. | ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection |
FDA applications (0)
No records yet.